These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 24976706)

  • 1. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues.
    Chen CH; Chiu YC; Lu SN; Lee CM; Wang JH; Hu TH; Hung CH
    World J Gastroenterol; 2014 Jun; 20(24):7686-95. PubMed ID: 24976706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy.
    Barone M; Iannone A; Di Leo A
    World J Gastroenterol; 2014 Jul; 20(26):8722-5. PubMed ID: 25024631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of HBsAg quantification for monitoring natural history and treatment outcome.
    Martinot-Peignoux M; Lapalus M; Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():125-32. PubMed ID: 23286856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B.
    Papatheodoridi M; Papatheodoridis G
    Cells; 2020 Feb; 9(2):. PubMed ID: 32093411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues.
    Liu S; Liu Z; Li W; Zhou B; Liang X; Fan R; Deng R; Hou J; Sun J
    Aliment Pharmacol Ther; 2020 Aug; 52(4):692-700. PubMed ID: 32613672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy.
    Wang ML; Chen EQ; Tao CM; Zhou TY; Liao J; Zhang DM; Wang J; Tang H
    Scand J Gastroenterol; 2017 Dec; 52(12):1420-1426. PubMed ID: 28880694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis.
    Song A; Lin X; Lu J; Ren S; Cao Z; Zheng S; Hu Z; Li H; Shen C; Chen X
    Front Immunol; 2021; 12():779347. PubMed ID: 34804072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.
    Tseng TC; Kao JH
    J Gastroenterol; 2013 Jan; 48(1):13-21. PubMed ID: 23090000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Nucleos(t)ide Analogues Discontinuation Relapse: Hepatitis B Virus RNA versus Hepatitis B Surface Antigen.
    Wu S; Li T; Liu F; Yin D; Zhang L; Wang L
    J Coll Physicians Surg Pak; 2024 May; 34(5):545-550. PubMed ID: 38720214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.
    Wei W; Wu Q; Zhou J; Kong Y; You H
    Int J Environ Res Public Health; 2015 Aug; 12(8):10039-55. PubMed ID: 26308024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B.
    Tout I; Lampertico P; Berg T; Asselah T
    Antiviral Res; 2021 Jan; 185():104992. PubMed ID: 33279523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients.
    Suárez E; Buti M; Rodríguez M; Prieto M; Pascasio-Acevedo JM; Casanovas T; Crespo J; Tapiador JAR; Gómez-Rodríguez R; Figueruela B; Diago M; Morillas RM; Zozaya JM; Calleja JL; Casado M; Molina E; Fuentes J; Simón MA
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):267-271. PubMed ID: 30576297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
    Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
    Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].
    Jia R; Wang WX; Gao YY; Luan JQ; Qiao F; Liu JY; Yuan JH; Cheng YQ; Wang FS; Fu JL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):666-672. PubMed ID: 34371537
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
    Chan HL; Thompson A; Martinot-Peignoux M; Piratvisuth T; Cornberg M; Brunetto MR; Tillmann HL; Kao JH; Jia JD; Wedemeyer H; Locarnini S; Janssen HL; Marcellin P
    J Hepatol; 2011 Nov; 55(5):1121-31. PubMed ID: 21718667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.